Research programme: antisense drug therapies - ugichem
Alternative Names: UgimersLatest Information Update: 16 Jul 2016
At a glance
- Originator ugichem
- Class Antisense elements
- Mechanism of Action Antisense RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Austria (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Austria (Parenteral)
- 28 May 2013 ugichem receives grant from Austrian Research Promotion Agency FFG for development of Ugimer® antisense therapies in Inflammation